Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree
Executive Summary
Whether randomized controlled clinical trials or observational studies are best for measuring the risks of long acting beta-2 adrenergic agonists remains unresolved after a two-day FDA advisory committee meeting